114
[1] Nocard, Roux, Borrel , Salimbeni et Dujardin- Beaumetz. Le microbe de la
péripneumonie. Annales Inst.Pasteur, 1898 ; 12 : 240-2.
[2] Borrel A, Dujardin-Beaumetz, Jeantet E., Jouan .Le microbe de la
péripneumonie. Ann. Inst.Pasteur, 1910 ; 94:168.
[3] Bordet J. La morphologie du microbe de la péripneumonie des bovidés.
Ann.Inst.Pasteur, 1910; 24: 161–7.
[4] Dienes L, Edsall G. Observations on the L-Organism of Klieneberger. Experimental
Biology and Medicine. 1937, 1; 36(5):740‑4.
[5] Eb F, Orfila J. Mycoplasmes génitaux. Rôle pathogène et diagnostic. Médecine et
Maladies Infectieuses. 1985 ; 15 (9) : 491-4.
[6] Berche P, Gaillard JL, Simonet M. Les bactéries des infections humaines. Ed.
Flammarion, Médecine -Sciences, Paris, 1988; 53: 506-13.
[7] Cassell GH1, Waites KB, Crouse DT, Rudd PT, Canupp KC, Stagno S, Cutter GR. Association of Ureaplasma urealyticum infection of the lower respiratory tract
with chronic lung disease and death in very-low-birth-weight infants. Lancet. 1988; 2(8605):240-5.
[8] Chanock RM, Hayflick L, Barile MF. Growth on artificial medium of an agent
associated with atypical pneumonia and its identification as a PPLO. Proceedings of the National Academy of Sciences. 1962; 48(1):41‑9.
[9] Tully JG, Taylor-Robinson D, Cole RM, Rose DL. A newly discovered
mycoplasma in the human urogenital tract. Lancet. 1981;1(8233):1288-91.
[10] Taylor-Robinson D. The discovery of Chlamydia trachomatis. Sex Transm
Infect. 2017; 93(1):10.
[11] Delcroix M. Infection gynécologique. Paris Masson, 1994.
[12] Barbeyrac B, Dupon M, et Bebearc. Infections à Chlamydia. EMC, maladies
115
[13] François E-B. Aspects microbiologiques des Chlamydiae. Méd. Mal. Infect, 1995 ;
10 :290-8.
[14] Le Minor L. , Véron M. Bactériologie médicale 2ème édition, 1989.
[15] Orfila J, Biendo M. Histoire naturelle des Chlamydiose. Rev.Méd.Interne , 1995; 17
(supp1) : S29-32.
[16] Ripa K T. Microbiological diagnosis of Chlamydia trachomatis infection. Infection,
1982; 10(1): S19-24.
[17] Tully J G., Bové J M., Laigret F., et al. Revised taxonomy of the class Mollicutes:
proposed elevation of a monophyletic cluster of arthropod-associated Mollicutes to ordinal rank (Entomoplasmatales ord. nov.), with provision for familial rank to separate species with nonhelical morphology (Entomoplasmataceae fam. nov.) from helical species (Spiroplasmataceae), and emended descriptions of the order
Mycoplasmatales, family Mycoplasmataceae. International Journal of Systematic and Evolutionary Microbiology, 1993; 43(2): 378-85.
[18] Johansson K-E, Pettersson B. Taxonomy of Mollicutes. Molecular Biology and
Pathogenicity of Mycoplasmas, Edited by Razin and Herrmann, Kluwer AcademicIPlenum Publishers, New York; 2002: 1-29.
[19] Dienes L, Bullivant S. Morphology and reproductive processes of the L forms of
bacteria II. Comparative study of L forms and mycoplasma with the electron microscope. Journal of bacteriology, J Bacteriol. 1968; 95(2): 672–87.
[20] Pilet C., Bourdon J L., Tomba B., Marchal N. Bactériologie Médicale et
vétérinaire, 1987, 353.
[21] Papierok G., Pautrat G., Escarguel C. Les Mycoplasmes : leur place en
microbiologie Revue française des labo, 1992 ; 244.
[22] Bayramova F, Jacquier N, Greub G. Insight in the biology of Chlamydia-related
bacteria. Microbes Infect. 2018; 20(7-8):432-40.
116
[24] Elwell C, Mirrashidi K, Engel J. Chlamydia cell biology and pathogenesis. Nat
Rev Microbiol. 2016; 14(6): 385-400.
[25] Barbeyrac B, Bebear C .Chlamydia. Med Mal Infect 1997; 27: 71-83.
[26] Kaltenboeck B, Kousoulas KG, Storz J. Structures of an allelic diversity and
relationships among the major outer membrane protein (ompA) genes of the four chlamydial species. J. Bacteriol 1993 ; 175 (2) : 487-502.
[27] Bébéar C, De Barbeyrac B, Pereyre S, Bébéar CM. Résistance aux antibiotiques
chez les Mycoplasmes et les Chlamydiae 2004 ; 6 (4) : 263-72.
[28] Beaber C, Beaber CM. Infections humaines à mycoplasmes. EMC.2007; 37 (391) :
63-9.
[29] http://www.invivogen.com/review-mycoplasma
[30] Rottem S, Razin S. Isolation of mycoplasma membranes by digitonin. J Bacteriol.
1972 ; 110(2): 699-705.
[31] Amar A, Rottem S, Kahane I, Razin S. Characterization of the mycoplasma
membrane proteins. VI. Composition and disposition of proteins in membranes from aging Mycoplasma hominis cultures. Biochim Biophys Acta. 1976 Mar 5;426(2):258-70.
[32] Hollingdale MR, Lemcke RM. Antigenic differences within the species
Mycoplasma hominis.. J. Hyg. Camb., 1970; 68 (3) : 469-77.
[33] Andersonn D.R. , M.F. Barille. Ultrastmcture of Mycoplasma Hominis.
J.Bacteriol., 1965 ; 90 (1) : 180 – 92.
[34] http://www.microbes-edu.org/etudiant/etudiants.html
[35] Poumarat F, Le grand D, Bergonié D. Propriétés générales des mycoplasmes et
hypervariabilité antigénique. Le Point Vétérinaire. 1996; 28(180): 761-7.
[36] Rottem S, Naot Y. Subversion and exploitation of host cells by mycoplasmas.
117
[37] http://www.pheculturecollections.org.uk/services /mycotestingeradication/mycocultureisolation.aspx
[38] http://www.ureaplasma.info/photogallery.php?photo_id=11
[39] http://www.ureaplasma.info/photogallery.php?photo_id=11
[40] Himmelreich R, Hilbert H, Plagens H, Pirkl E, Li B-C, Herrmann R. Complete
Sequence Analysis of the Genome of the Bacterium Mycoplasma Pneumoniae. Nucleic Acids Research. 1996; 24(22): 4420‑49.
[41] Roachford OSE, Nelson KE, Mohapatra BR. Comparative genomics of four
Mycoplasma species of the human urogenital tract: Analysis of their core genomes and virulence genes. International Journal of Medical Microbiology. 2017; 307(8): 508‑20.
[42] Barnes RC. Laboratory diagnosis of human Chlamydial infections.Clin Microbiol
Rev. 1989; 2 (2) :119-36.
[43] De Barbeyrac B, Bébéar C. Histoire naturelle des infections à Chlamydia
Physiopathologie des infections à Chlamydia : conséquences diagnostiques et thérapeutiques. Arch Pediatr. 2005; 12 (sup 1): S26-31.
[44] Choroszi-krol I, Frej-Madrzak M, Jama-Kmiecik A, Bober T, Sarowska J.
Characteristics of the Chlamydia trachomatis species-Immunopathology and infections. Adv Clin Exp Med. 2012; 21 (6): 799-808.
[45] Kosma P. Chlamydial lipopolysaccharide. Biochimica et Biophysica Acta (BBA) -
Molecular Basis of Disease. 1999; 1455 (2-3) :387-402.
[46] Peuchant O, Cazanave C, de Barbeyrac B. Infections humaines à Chlamydiae.
EMC Maladies infectieuses. 2012; 9: 1-19.
[47] Matsumoto A, Manire GP. Electron microscopic observations on the fine structure
118
[48] Liechti GW, Kuru E, Hall E, Kalinda A, Brun YV Van Nieuwenhze M et al. A
new metabolic cell-wall labeling method reveals peptidoglycan in Chlamydia trachomatis. Nature 2014; 506 (7489) : 507-10.
[49] Mariana C, Demetra S, Veaceslav M, Veronica L, Grigore M, Corali B. Host
Immune Response to Chlamydia Infection. Chlamydia, 2011; 4: 75- 90.
[50] Feher VA, Randall A, Baldi P, Bush RM, De la Maza LM, Amaro RE. A
3-dimensional trimeric ß-barrel model for Chlamydia MOMP contains conserved and novel elements of Gram negative bacterial porins. PLOS ONE. 2013; 8 : 1-11.
[51] De Barbeyrac B, Bianchi A, Bébéar C. Actualités sur les infections à Chlamydia.
Immuno-analyse & Biologie Spécialisée. 2000 ; 15(4) :227-32.
[52] Schaechter M, Eeistein BI. Microbiologie et pathologie infectieuse. Ed de boeck,
1999.
[53] Hajikhani B, Motallebi T, Norouzi J, Bahador A, Bagheri R, Asgari S et al.
Classical and molecular methods for evaluation of Chlamydia trachomatis infection in women with tubal factor infertility. J Reprod Infertil. 2013; 14 (1): 29-33.
[54] Abdel Rahman YM, Rose LA, Belland RJ. Developmental expression of
non-coding RNAs in Chlamydia trachomatis during normal and persistent growth. Nucleic Acids Res. 2010; 39:1843- 54.
[55] Subtil A, Dautry-Varsat A. Chlamydia: five years A.G (after genome). Curr Opin
Microbiol. 2004;7 (1):85-92.
[56] Beatty WL, Morrison RP, Byrne GI. Persistent Chlamydiae: from cell culture to a
paradigm for chlamydial pathogenesis. Microbiol Rev. 1994; 58 (4): 686-99.
[57] Chopra I, Storey C, Falla TJ, Pearce JH. Antibiotics, peptidoglycan synthesis and
genomics: the chlamydial anomaly revisited. Microbiology. 1998;144 (10):2673‑8.
[58] Bachmann NL, Polkinghorne A, Timms P. Chlamydia genomics: providing novel
119
[59] Corsaro D, Le Faou A,Ed Larpent JP. Microbiologie cellulaire et moléculaire des
Chlamydia. Eds Lavoisier 2002 ;1: 17-26.
[60] Bellulo S, Bosdure E, David M, Rolain JM, Gorincour G, Dubus JC. Pneumonie
du nourrisson à Chlamydia trachomatis : à propos de 2 cas atypiques. Arch Pediatr. 2012; 19 (2): 142-5.
[61] Zhong G. Chlamydial Plasmid-Dependent Pathogenicity. Trends in Microbiology.
2017; 25(2):141‑52.
[62] Ripa T, Nilsson PA. "A Chlamydia trachomatis strain with a 377-bp deletion in the
cryptic plasmid causing false-negative nucleic acid amplification tests." Sexually transmitted diseases, 2007; 34(5): 255-6.
[63] Beaber CM. Pathogenesis and laboratory diagnosis of Mycoplasma pneumoniae
infections. Arch Pediatr. 2008; 15 (7): 1253-6.
[64] Waites KB, Talkington D. Mycoplasma pneumoniae and its role as a human
pathogen. Clin Microbiol Rev. 2004; 17(4): 697–728.
[65] Judlin P. Mycoplasmes génitaux. Gynécologie Obstétrique & Fertilité [Internet].
2003 ; 31(11):954‑9.
[66] Gnarpe J, Lundback A, sundelof B, Gnarpe H. Prevalence of Mycoplasma
pneumonia in subjectively healthy individuals. Scand J Infect Dis. 1992; 24 (2): 161-4
[67] Prescott A, Mitchell F. Balish B. Epidemiology, clinical manifestations,
pathogenesis and laboratory detection of Mycoplasma pneumonia infections. FEMS Microbiol Rev. 2008 ;32(6):956-73.
[68] Taylor-Robinson D. Mollicutes in vaginal microbiology: Mycoplasma hominis ,
Ureaplasma urealyticum, Ureaplasma parvum and Mycoplasma genitalium. Research in Microbiology. 2017 ;168(9‑10): 875‑81.
120
[69] Bao Y-X, Li J, Tian Y, Liu Q-H, Bao J. Atopy: A risk factor of refractory
mycoplasma pneumoniae pneumonia? . The Clinical Respiratory Journal . 2016; 11(6): 931‑4.
[70] Silva J, Cerqueira F, Teixeira AL, Bicho MC, Campainha R, Amorim J, et al.
Genital mycoplasmas and ureaplasmas in cervicovaginal self-collected samples of reproductive-age women: prevalence and risk factors. International Journal of STD & AIDS . 2018; 29(10): 999‑1006.
[71] Perol Y, LaTrille J. Diagnostic biologique des infections humaines à mycoplasmes.
Med Mal Infect. 1975; 5: 265-76.
[72] Weidner W, Krause W, Scheiffer HG, Brunner H, Freidrich HJ. Ureaplasma
infection of the male urogenital tract in particular prostatistis and semen quality. Urol Int.1985; 40 (1): 5-9.
[73] Marchello C, Dale AP, Thai TN, Han DS, Ebell MH. Prevalence of Atypical
Pathogens in Patients With Cough and Community-Acquired Pneumonia: A Meta-Analysis. Ann Fam Med. 2016 ;14(6): 552-66.
[74] Baumann, L., Cina, M., Egli-Gany, D., Goutaki, M., Halbeisen, F. S., Lohrer, G.-R. et al. Prevalence of Mycoplasma genitaliumin different population groups:
systematic review and meta-analysis. Sexually Transmitted Infections, 2018; 94(4), 255–62.
[75] Khosropour CM, Manhart LE, Gillespie CW, Lowens MS, Golden MR, Jensen
NL, Kenny GE, Totten PA. Efficacy of standard therapies against Ureaplasma
species and persistence among men with non-gonococcal urethritis enrolled in a randomised controlled trial. Sex Transm Infect. 2015; 91(5):308-13.
[76] Mpiga P, Ravaoarinoro M. Chlamydia trachomatis persistence : an update.
Microbiol Res. 2005; 161(1): 9-19.
[77] Sarlangue J, Castella C. Infections à Chlamydia trachomatis du nouveau-né et du
121
[78] Norman J. Epidemiology of female genital Chlamydia trachomatis infections. Best
Pract Res Clin Obstet Gynaecol. 2002; 16(6): 775-78.
[79] Wyrick PB. Chlamydia trachomatis persistence in vitro -an overview. J Inf Dis.
2010; 201(sup 2): S88-95.
[80] Eb F. Chlamydia psittaci : Epidémiologie, pouvoir pathogène et diagnostic.
Médecine et Maladies Infectieuses. 1993;23(12):919‑24.
[81] Falsey AR., Walsh EE. Transmission of Chlamydia pneumoniae. J Infect Dis. 1993;
168(2):493-6.
[82] https://trachoma.org/about-trachoma
[83] De Barbeyrac B., Clerc M., Raherison S., Bébéar CM, Bébéar C. Infections
humaines à chlamydiae: Diagnostic biologique et épidémiologie. Revue Francophone Des Laboratoires. 2007; 37(391): 71–6.
[84] Hocking JS, Huston WM, Chen M. Chlamydia trachomatis Infection. In: Sexually
Transmitted Infections in HIV-Infected Adults and Special Populations .Springer International Publishing. 2017:51‑69.
[85] Global incidence and prevalence of selected curable sexually transmitted infections. OMS, Genève 2012.
[86] Organisation mondiale de la santé, Who.EmRO,www.who.int , 2016.
[87] Flexor G, Clarisson JGM, De Babeyrac , Péronne C, Truchis P. Annales de
Dermatologie et de vénéreologie. 2010; 137(2) :117-20.
[88] Totten S, Mac Leanr, Payne E, Severini A. Chlamydia and lymphogranuloma
vénérum in canada 2003-2012. Summary report can commun Dis Rep 2015; 41(2): 20-5.
[89] OMS Organisation mondiale de la santé :
http://www.emro.who.int/fr/media/actualites/morocco-eliminates-trachoma-the-leading-infectious-cause-of-blindness.html
122
[90] Hames C., Halbedel S., Hoppert M., Frey J., Stülke J. Glycerol Metabolism Is
Important for Cytotoxicity ofMycoplasma pneumoniae. Journal of Bacteriology, 2008; 191(3), 747–53.
[91] Ben-Menachem G, Himmelreich R, Herrmann R, Aharonowitz Y, Rottem S.
The thioredoxin reductase system of mycoplasmas. Microbiology. 1997; 143(6): 1933-40.
[92] Rottem S. Interaction of mycoplasmas with host cells. Physiological reviews
2003;83(2) : 417-432.
[93] Sachse K, Grajetzki C, Rosengarten R, Hänel I, Heller M, Pfützner H.
Mechanisms and factors involved in Mycoplasma bovis adhesion to host cells. Zentralbl. Bakteriol. 1996; 284, 80-92.
[94] Razin S, Jacobs E. Mycoplasma adhesion. Journal of General Microbiology. 1992;
138(3), 407– 22.
[95] Mulongo M., Prysliak T., Scruten E., Napper S., Perez-Casal J. In vitro infection
of bovine monocytes with Mycoplasma bovis delays apoptosis and suppresses production of gamma interferon and tumor necrosis factor alpha but not interleukin-10. Infect.Immun. 2014; 82, 62-71.
[96] McGowin CL, Totten PA. The Unique Microbiology and Molecular Pathogenesis
of Mycoplasma genitalium. The Journal of Infectious Diseases [Internet]. 2017; 216(suppl 2): S382‑8.
[97] Dehon PM, McGowin CL. Mycoplasma genitalium infection is associated with
microscopic signs of cervical inflammation in liquid cytology specimens. J Clin Microbiol. 2014; 52:2398–405.
[98] Britton AP, Ruhnke HL, Miller RB, Johson WH, Leslie KE, Rosendal S. In vitro
exposure of bovine morulae to Ureaplasma diversum. Canadian Journal of Veterinary Research. 1987; 51: 198-203.
123
[99] Razin S, Yogev D, Naot Y. Molecular biology and pathogenicity of mycoplasmas.
Microbiology and Molecular Biology Reviews, 1998; 62, 1094-156.
[100] Sanchis R, Abadie G, Lambert M, Cabasse E, Dufour P, Guibert JM et Pépin M. Inoculation of lactating ewes by the intramammary route with Mycoplasma
agalactiae: Comparative pathogenicity of six field strains. Veterinary Research, 2000; 31(3): 329-37.
[101] Citti C, Nouvel L-X, Baranowski E. Phase and antigenic variation in
mycoplasmas. Future Microbiology . 2010 ; 5(7):1073‑85.
[102] Mah T.F, O'Toole GA. Mechanisms of biofilm resistance to antimicrobial agents.
Trends Microbiol.2001; 9 (1): 34-9.
[103] Simmons WL, Dybvig K. Mycoplasma Biofilms Ex Vivo and In Vivo. FEMS
Microbiology Letters. 2009; 295(1): 77-81
[104] Feng M, Schaff AC, Cuadra Aruguete SA, Riggs HE, Distelhorst SL, Balish MF.
Development of Mycoplasma pneumoniae biofilms in vitro and the limited role of motility. International Journal of Medical Microbiology. 2018 avr;308(3):324‑34.
[105] De Barbeyrac B, Peuchant O, Ranger-Rogez S. Bactéries cytoparasites
obligatoires." Bactériologie Médicale (Troisième Édition). 2016. 497-514.
[106] Mehlitz A, Rudel T. Modulation of host signaling and cellular responses by
Chlamydia. Cell Communication and Signaling . 2013;11(1):90.
[107] Moulder JW, Levy NJ, Schulman LP. Persistent infection of mouse fibroblasts (L
cells) with Chlamydia psittaci: evidence for a cryptic chlamydial form. Infect Immun 1980;30(3) :874-83
[108] Hogan RJ, Mathews SA, Mukhopadhyay S, Summersgill JT, Timms P.
Chlamydial persistence: beyond the biphasic paradigm. Infect Immun 2004; 72 (4):1843-55.
[109] Stephens RS. The cellular paradigm of chlamydial pathogenesis. Trends Microbiol
124
[110] Belland RJ, Ouellette SP, Gieffers J, Byrne GI. Chlamydia pneumoniae and
atherosclerosis. Cellular Microbiology. 2004; 6(2): 117-27.
[111] Campbell LA., Rosenfeld ME. Infection and Atherosclerosis Development.
Archives of Medical Research, 2015; 46(5): 339 – 50.
[112] Li D, Liu L, Chen H, et al. LOX-1 mediates oxidized low-density
lipoprotein-induced expression of matrix metalloproteinases in human coronary artery endothelial cells. Circulation. 2003; 107(4): 612-7.
[113] Tumurkhuu G, Dagvadorj J, Porritt RA, Crother TR, Shimada K, Tarlin EJ. Chen S. Chlamydia pneumoniae Hijacks a Host Autoregulatory IL-1β Loop to Drive
Foam Cell Formation and Accelerate Atherosclerosis. Cell Metab. 2018; 28(3): 432-48.
[114] Anderson JL, Muhlestein JB. Antibiotic trials for coronary heart disease. Texas
Heart Institute Journal, 2004; 31(1): 33-8.
[115] Kelly KA. Cellular immunity and Chlamydia genital infection: Induction,
recruitment, and effectors mechanisms. International Reviews of Immunology. 2003; 22(1):3-41.
[116] Witkin SS. Immunological aspects of genital chlamydia infections. Best Practice
and Research in Clinical Obstetrics and Gynaecology. 2002; 16(6): 865-74.
[117] Shimada K, Crother TR. , Arditi M. Innate immune responses to Chlamydia
pneumoniae infection: role of TLRs, NLRs, and the inflammasome. Microbes Infect. 2012; 14(14): 1301–07.
[118] Roblot F, Bourgoin A, Godet C. Infections à Mycoplasma pneumonia, EMC, 2008. [119] Lieberman D, Printz S, Ben-Yaakov M, Lazarovich Z, Ohana B, Friedman MG,
et al. Atypical pathogen infection in adults with acute exacerbation of bronchial
125
[120] Kassisse E, García H, Prada L, Salazar I, Kassisse J. Prevalence of Mycoplasma
pneumoniae infection in pediatric patients with acute asthma exacerbation. Archivos argentinos de pediatria .2018;116(3): 179-85.
[121] Kumar S, Roy RD, Sethi G, Saigal SR. Mycoplasma pneumoniae infection and
asthma in children. Tropical Doctor. 2018; 1–3.
[122] Kraft M, Cassell GH, Pak J, Martin RJ. Mycoplasma pneumoniae and Chlamydia
pneumoniae in asthma: effect of clarithromycin. Chest. 2002; 121(6): 1782-8.
[123] Normansell R, Sayer B, Waterson S, Dennett E J, Del Forno M, Dunleavy A.
Antibiotics for exacerbations of asthma. Cochrane Database of Systematic Reviews. 2018;6.
[124] Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH.
Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma. Chest. 2000;118: 1826-7.
[125] Arfaatabar M, Aminharati F, Azimi G, Ashtari A, Pourbakhsh SA, Masoorian E, Pourmand MR. High frequency of Mycoplasma pneumoniae among patients
with atypical pneumonia in Tehran, Iran. GERMS, 2018;8(3):126-33.
[126] Sharma L, Losier A, Tolbert T, Dela Cruz CS, Marion CR. Atypical Pneumonia.
Clinics in Chest Medicine . 2017;38(1):45‑58
[127] Gendrel D. Mycoplasma pneumoniae et infections respiratoires aiguës. Revue
française d’allergologie et d’immunologie clinique. 2007; 47: 442–5.
[128] Hardy RD, Jafri HS, Olsen K, Wordemann M, Hatfield J, Rogers BB. Elevated
cytokine and chemokine levels and prolonged pulmonary airflow resistance in a murine Mycoplasma pneumonia model. Infect Immun. 2001; 69(6): 3869–76.
[129] Moi H, Blee K, Horner PJ. Management of non-gonococcal urethritis. BMC
Infectious Diseases . 2015; 15(1): 294.
[130] Alcaraz I, Dupin N, Janier M et al. Mycoplasmes génitaux. Ann Dermatol
126
[131] Bebear CM. Mycoplasmes et chlamydia. Elsevier Masson SAS. 2002.
[132] Horner PJ, Martin DH. Mycoplasma genitalium Infection in Men. The Journal of
Infectious Diseases, 2017; 216(suppl2), S396 – 405.
[133] Jensen JS. Mycoplasma genitalium: the aetiological agent of urethritis and other
sexually transmitted diseases.. J Eur Acad Dermatol Venerol. 2004; 18: 1-11.
[134] Cox C, Watt AP, McKenna JP, Coyle PV. Mycoplasma hominis and Gardnerella
vaginalis display a significant synergistic relationship in bacterial vaginosis. European Journal of Clinical Microbiology & Infectious Diseases, 2016; 35(3): 481- 7.
[135] Fichorova R, Fraga J, Rappelli P, Fiori PL. Trichomonas vaginalis infection in
symbiosis with Trichomonasvirus and Mycoplasma. Research in Microbiology, 2017;168(9-10),:882–91.
[136] Uuskula A, Kohl PK. Genital mycoplasmas, including M.genitalium, asexually
transmitted agents. Int J STD AIDS. 2002; 13: 79-85.
[137] Dehon PM, Hagensee ME., Sutton KJ., Oddo HE., Nelson N et McGowin CL.
Histological Evidence of Chronic Mycoplasma genitalium–Induced Cervicitis in HIV-Infected Women: A Retrospective Cohort Study. Journal of Infectious Diseases,2016; 213(11), 1828–35.
[138] Nunez-Troconis JT. M. Hominis and U. urealyticum in different gynecologie
diseases. Invest Clin. 1999; 40: 9-24.
[139] Judlin P, Zaccabri A, Koebele A. Salpingites aigues non spécifiques. encly Med
Chir, Editions scientifiques et medicales. ELSEVIER SAS. 2001; 470: 9-10.
[140] Alcaraz I, Dupin N, Janier M et al. Mycoplasmes génitaux. Ann Dermatol
Venereol. Ann Dermatol Venereol. 2016;143(11):718-9.
[141] Clausen HF, Fedder J, Drasback M, et al. Serological investigation of
127
[142] Cassel GH, Cole BC. Mycoplasmas as agent of humain diseases. N Engl J Med.
1981; 304(2):80-9.
[143] Robinson D. Genital mycoplasma infections. Clinics in Laboratory Medicine. 1989;
9(3): 501-23.
[144] Bebear C, Fourmaux S Fleury HJA. Diagnostic biologique des MST chez la
femme. Med Mal Infect. 1994; 24(4): 349-60.
[145] Tsevat DG, Wiesenfeld HC, Parks C, Peipert JF. Sexually transmitted diseases
and infertility. American Journal of Obstetrics and Gynecology. 2017 ; 216(1):1‑9.
[146] Clausen HF, Fedder J, Drasback M, et al. Serological investigation of
M.genitalium in infertile women. Hum Reprod. 2001; 16(9): 1866-74.
[147] Svenstrup HF, Fedder J, Kristoffersen SE, Trolle B, Birkelund S, Christiansen G. Mycoplasma genitalium, Chlamydia trachomatis, and tubal factor infertility- a
prospective study. Fertil Steril 2008; 90(3): 513-20.
[148] Idahl A, Jurstrand M, Olofsson JI, Fredlund H. Mycoplasma genitalium serum
antibodies in infertile couples and fertile women. Sex Transm Infect. 2015; 91(8): 589-91.
[149] Møller B, Taylor-Robinson D, Furr PM, Toft B, Allen J. Serological evidence
that chlamydiae and mycoplasmas are involved in infertility of women. J Reprod Fertil 1985; 73: 237-40.
[150] Spandorfer SD, Neuer A, Giraldo PC, Rosenwaks Z, Witkin SS. Relationship of
abnormal vaginal flora, pro-inflammatory cytokines and idiopathic infertility in women undergoing IVF. J Reprod Med. 2001; 46 (9): 806–10.
[151] Witkin SS, Kligman I, Grifo JA, Rosenwaks ZU. urealyticum and M.hominis
detected by polymerase chain reaction in the cervices of women undergoing IVF: prevalence and consequences. J Assist Reprod Genet. 1995; 12(9): 610 - 4.
[152] Ko EY, Sabanegh ES Jr & Agarwal A. Male infertility testing: reactive oxygen
128
[153] Huang C, Zhu H L, Xu KR., Wang, S. Y., Fan LQ., Zhu WB. Mycoplasma and
ureaplasma infection and male infertility: a systematic review and meta-analysis. Andrology, 2015(5), 809 -16.
[154] Lingwood CA, Schramayr S, Quinn P. Male germ cell specific
sulfogalactoglycerolipid is recognized and degraded by mycoplasmas associated with male infertility. J Cell Physiol 1990; 142(1):170–6.
[155] Bielanski A, Devenish J, Phipps-Todd B. Effect of Mycoplasma bovigenitalium in
semen on fertilization and association with in vitro produced morula and blastocyst stage embryos. Theriogenology. 2000; 53(6): 1213–23.
[156] Nigro G, Mazzocco M, Mattia E, Di Renzo GC, Carta G, Anceschi MM. Role of
the infections in recurrent spontaneous abortion. The Journal of Maternal-Fetal & Neonatal Medicine, 2011; 24(8): 983 - 9.
[157] Latino MA, Botta G, Badino C, Maria DD., Petrozziello A, Sensini A, Leli C.
Association between genital mycoplasmas, acute chorioamnionitis and fetal pneumonia in spontaneous abortions. Journal of Perinatal Medicine, 2018 ; 46(5) : 503–8.
[158] Aujard Yannick. Infections bactériennes néonatales spécifiques. Infections
néonatales: Bactériennes, mycosiques, parasitaires et virales, 2015 : 107.
[159] Panero A, Pacifico L, Rossi N, et al. C. Ureaplasma urealyticum as a cause of
pneumonia in preterm infants: analysis of the white cell response. Arch Dis Child Fetal Neonatal Ed 1995; 73 (1): F37 – 40.
[160] Biran V, Dumitrescu AM, Doit C, et al. Ureaplasma parvum meningitis in a
full-term newborn. Pediatr Infect Dis J. 2010; 29(12):1154.
[161] Dupin N, Janier M, Bouscarat F, Vernay-Vaisse C, Spenatto N, Vermersch-Langlin A. Infection à Chlamydia trachomatis. Annales de Dermatologie et de
129
[162] O’Connell CM, Ferone ME. Chlamydia trachomatis Genital Infections. Microbial Cell . 2016; 3(9): 390‑403.
[163] Dehghan Marvast L, Aflatoonian A, Talebi AR, Ghasemzadeh J, Pacey AA.
Semen inflammatory markers andChlamydia trachomatisinfection in male partners of infertile couples. Andrologia. 2015;48(7):729‑36.
[164] Eley A, Pacey AA. The value of testing semen for Chlamydia trachomatis in men of
infertile couples.Int J Androl 2011; 34 (5):391-401.
[165] Reddy SP, Yeturu SR, Slupik R. Chlamydia trachomatis in adolescents: A review.
J Pediatr Adolesc Gynecol 1997; 10-59-72.
[166] Manifestations dermatologiques de l’infection par le virus de l’immunodéficience
humaine. Médix, www.médix.free.fr Publié en 2017; page 7634.
[167] Lefevre JC, Averous S, Candillier C, Bauriaud R, Lareng MB. Les infections
génitales basses à Chlamydia trachomatis dans la région Midi-Pyrénées-Etude clinique et épidémiologique. Med Mal Infect 1987; 17 (1) :19-24.
[168] Quentin R, Verdon R. Les infections génitales hautes : bases microbiologiques du
diagnostic et du traitement. J Gynécol Obstet Biol Reprod 2012; 41(8): 850-63.
[169] Cravello L. Infections génitales de la femme Leucorrhées. La revue du praticien
2001; 51: 2255-61.
[170] Herzog SA, Althaus CL, Heijne JCM, Oakeshott P, Kerry S et al .Timing of
progression from Chlamydia trachomatis infection to pelvic inflammatory disease:amathematical modelling study. BMC Infect Dis. 2012; 12:187.
[171] Haggerty CL, Gottlieb SL, Taylor BD, Low N, Xu F, Ness RB. Risk of sequelae after Chlamydia trachomatis genital infection in women. J Inf Dis 2010; 201(supp2): S134-55.
[172] Jacquemard F. Syndrome infectieux foetal. EMC-Pédiatrie 2004 ; 1: 296-323. [173] Henry Suchet J. Infection à Chlamydia trachomatis chez la femme. Rev Med
130
[174] Weström L., PA Mardh. Chlamydial salpingitis. British Medical Bulletin, 1983 ;39
(2) :145-50.
[175] Malhotra M, Sood S, Mukherjee A, et al. Genital Chlamydia trachomatis: an
update. Indian J Med Res 2013;138 (3) : 303 – 16.
[176] Cohen I, Veille JC, Calkins BM. Improved pregnancy outcome following
successfull treatment of Chlamydia infection. JAMA, 1990;263:3160–3.
[177] Oury JF. Infections bactériennes et parasitaires au cours de la grossesse. Infections
néonatales: Bactériennes, mycosiques, parasitaires et virales, 2015: 47.
[178] Jain S. Perinatally acquired Chlamydia trachomatis associated morbidity in young
infants. J Matern Fetal Med, 1999;8 (3):130 -3.
[179] Darville T. Chlamydia trachomatis infections in neonates and young children. Semin
Pediatr Infect Dis 2005;16 (4): 235–44.
[180] Caumes E, Dupin N, Janier M, Chartier C, Viraben R, Maatouk I.
Lymphogranulome vénérien (maladie de Nicolas Favre). Annales de Dermatologie et de Vénéréologie. 2016;143(11):736‑8.
[181] De Vrieze NH, de Vries HJ. Lymphogranuloma venereum among men who have
sex with men.An epidemiological and clinical review. Expert RevAnti Infect, 2014; 12(6):697–704.
[182] Stamm WE,Holmes KK, Sparling PF, Stamm WE, Piot P, Wasserheit JN, Corey L. Lymphogranuloma venereum. Sexually transmitted diseases 4eéd New
York, NY: McGraw-Hill, 2008; 595–605.
[183] De Vrieze NH, van Rooijen M, Schim van der Loeff MF, de Vries HJ. Anorectal
and inguinal lymphogranuloma venereum among men who have sex with men in